Starting approved ATTR-CM drug earlier may cut risk of heart problems

Analysis of 2-year study data also show better quality of life with med

Written by Marisa Horak, MS |

A clinician wearing a white lab coat and a mask takes a blood sample from an older man.

(Image from iStock)

For people with transthyretin amyloid cardiomyopathy (ATTR-CM), starting treatment earlier with the approved med Amvuttra (vutrisiran) can reduce the risk of serious heart problems and help maintain quality of life over time.

That’s according to a new analysis of two-year data tracking outcomes among participants in the open-label extension portion of the large, late-stage clinical trial whose results led to the drug’s approval. Those data, along with the results of other analyses, showed better outcomes with the injection therapy when people with ATTR-CM — which is marked by accumulating heart damage that can ultimately lead to heart failure — began taking Amvuttra early in the disease’s course.

“ATTR-CM is a progressive disease, making it critical to intervene before patients experience further irreversible decline,” Sarah Cuddy, MD, a study author from Brigham and Women’s Hospital and Harvard Medical School, said in a company press release from Alnylam Pharmaceuticals, which markets the therapy.

Cuddy presented the findings at the American Heart Association (AHA) Scientific Sessions 2026, held Nov. 6-9 in Chicago. Her oral presentation was titled “2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.”

In people with ATTR-CM, the protein transthyretin (TTR) forms toxic clumps that damage the heart. Amvuttra, approved in both the U.S. and the European Union, works to reduce TTR levels using a molecular technology called RNA interference (RNAi), which basically reduces the amount of the protein made by the body’s cells.

According to Cuddy, “these findings reinforce the importance of considering TTR silencing early in the course of disease to preserve patients’ health and quality of life for as long as possible.”

Recommended Reading
An illustration shows different types of medications, from pills and tablets to injections and infusions.

Real-world Amvuttra safety signals mostly match known profile

Amvuttra’s approvals for ATTR-CM were based mainly on data from the Phase 3 HELIOS-B trial (NCT04153149), which tested the therapy against a placebo in more than 600 adults over three years. The HELIOS-B results showed the therapy significantly reduced the risk of cardiovascular events, such as heart-related hospitalizations and urgent heart failure visits, among patients.

Participants completing the trial’s placebo-controlled portion had the option to enter its open-label extension, in which all were treated with Amvuttra for two years. The newly presented data concern pooled results from both portions of the trial.

Better outcomes seen with Amvuttra when started early on

The researchers compared outcomes for participants originally assigned to then-experimental therapy versus those who started on the placebo and switched to Amvuttra three years later, when entering the extension portion.

The results showed that individuals who started Amvuttra earlier had a significantly lower long-term risk of recurrent cardiovascular events — by 41% — compared with those with delayed treatment.

[These long-term data] are particularly compelling because they demonstrate that patients treated continuously with [Amvuttra] experienced more favorable outcomes than those who initiated treatment later.

Subgroup analyses showed that Amvuttra reduced risk by 50% in participants not on Vyndamax (tafamidis), another ATTR-CM-approved therapy, at the start of the study, and by 23% in the overall trial population. All these differences were statistically significant, meaning it’s extremely unlikely the difference is due to random chance.

The combined risk of recurrent cardiovascular events or death of any cause was also significantly reduced, by 41%, among participants who started Amvuttra earlier, with consistent trends seen in the subgroup analyses. Quality of life scores and levels of heart damage markers also generally favored early-start Amvuttra, the researchers noted.

Pushkal Garg, MD, chief research and development officer at Alnylam, said the new data “reinforce the strength of TTR silencing as a foundational approach to ATTR-CM care, and show the potential of RNAi therapeutics to translate deep, sustained target suppression into meaningful long-term outcomes for patients.”

Long-term safety data were consistent with Amvuttra’s known profile, without reports of new safety signals, according to the researchers.

“The sustained treatment effects observed with Amvuttra across multiple measures of cardiovascular health during the five years of HELIOS-B strengthen the evidence that early and continuous TTR silencing at the source can change the course of a rapidly progressive disease,” Garg said.

Cuddy added that these long-term data “are particularly compelling because they demonstrate that patients treated continuously with [Amvuttra] experienced more favorable outcomes than those who initiated treatment later.”

Recommended Reading
A bar graph, a line graph, a pie chart, and a pill bottle are seen sandwiched between the words

New analyses back Amvuttra as first-line treatment for complex heart cases

Data also show drug keeps exercise ability stable

In a separate presentation, this one titled “The Effect of Vutrisiran on Cardiopulmonary Response to Exercise in ATTR-CM: The HELIOS-B CPET and Stress Echocardiography Substudy,” researchers shared data from a single-center HELIOS-B substudy that evaluated Amvuttra’s effect on exercise capacity. The team noted that ATTR-CM is marked by “a progressive reduction in exercise tolerance.”

This analysis compared two-year exercise-related outcomes between 25 participants treated with Amvuttra and 23 given the placebo. Key outcomes covered were peak VO2, a measure of how well the body can utilize oxygen, and chronotropic response, which assesses how well the heart can speed its beating during exercise.

In the placebo group, all of these measures tended to get worse over the course of two years of follow-up, the data showed. In contrast, among those given Amvuttra, average scores on exercise-related measures were largely stable or even slightly improved. The team noted that none of these participants were on other ATTR-CM disease-modifying therapies during the study period.

The researchers stressed that this analysis was limited to a small number of patients at one center. Still, per the team, the data suggest that Amvuttra “confers a treatment effect across several components of cardiopulmonary response to exercise [including] preservation of exercise capacity and chronotropic response.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.